Halozyme Therapeutics HALO Payment To Acquire In Process Research And Development, Net Of Cash Acquired

Payment To Acquire In Process Research And Development, Net Of Cash Acquired at other companies

Johnson & JohnsonJNJ

$96.25M-78.4%

BrukerBRKR

$7.35M—

Mid-America Apartment CommunitiesMAA

$75.26M+13.6%

Spyre Therapeutics, Inc.SYRE

$30M—

AccentureACN

$204.33M-29.0%

Cboe Global MarketsCBOE

$0-100%

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept halo:PaymentToAcquireInProcessResearchAndDevelopmentNetOfCashAcquired.

The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's payment to acquire in process research and development, net of cash acquired.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's payment to acquire in process research and development, net of cash acquired?: Halozyme Therapeutics (HALO) reported payment to acquire in process research and development, net of cash acquired of $71.94M in Q4 2025.
What does payment to acquire in process research and development, net of cash acquired mean?: Cash payments made to acquire intellectual property, research projects, or development-stage assets that have not yet reached commercial viability. This is a critical indicator of R&D-focused investment strategies in pharmaceutical and biotech sectors.